Amitabh Chandra
Henry and Allison McCance Family Professor of Business Administration
Amitabh Chandra is the Henry and Allison McCance Family Professor of Business Administration at Harvard Business School where he is the Faculty Chair of the joint MS/MBA program in the life-sciences, the Faculty Chair of the executive education program in the life-sciences, chairs the Pagliuca Harvard Life Lab committee, and serves on the selection committee of the Blavatnik Fellows. Professor Chandra is the Ethel Zimmerman Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government.
Professor Chandra's research focuses on innovation, pricing, and capital allocation in the biopharmaceutical industry, value in health care, medical malpractice, racial disparities in healthcare, and discovering new methods for treating Alzheimer's. His research has been supported by the National Institute of Aging, the National Institute of Child Health and Development, the Robert Wood Johnson Foundation, and has been published in the American Economic Review, the Journal of Political Economy, the Quarterly Journal of Economics, the New England Journal of Medicine, the Journal of the American Medical Association, and Science.
Chandra serves on the Congressional Budget Office's Panel of Health Advisors and has testified to the United States Senate and the United States Commission on Civil Rights. He has served as Massachusetts’ Special Commissioner on Provider Price Reform, and has advised federal and state governments on health care reform.
Professor Chandra is an elected member of the American Academy of Arts and Sciences, the National Academy of Medicine, the National Academy of Social Insurance, the first-prize recipient of the Upjohn Institute’s Dissertation Award, the NIHCM Foundation Health Care Research Award, the Kenneth Arrow Award for best paper in health economics, the Eugene Garfield Award for the impact of medical research, and the American Society of Health Economists (ASHE) medal. which is given to an economist age 40 or under who has made the most significant contributions to the field of health economics.